ArticleMolecular pharmacology2017
Identification of AICP as a GluN2C-Selective
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Molecular pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Design of (Journal of medicinal chemistry · 2025Article
- Evaluation of allosteric N-methyl-d-aspartate receptor modulation by GluN2A-selective antagonists using pharmacological equilibrium modeling.Molecular pharmacology · 2025Article
- Artificial intelligence insight on structural basis and small molecule binding niches of NMDA receptor.Computational and structural biotechnology journal · 2025Article
- Discovery of GluN2A subtype-selectiveActa pharmaceutica Sinica. B · 2024Review
- Article
- Cocaine preference and neuroadaptations are maintained by astrocytic NMDA receptors in the nucleus accumbens.Science advances · 2022Article
- Derivatives of (Journal of medicinal chemistry · 2022Article
- Discovery of (Frontiers in chemistry · 2022Article
- Astrocytic NMDA Receptors in the Basolateral Amygdala Contribute to Facilitation of Fear Extinction.The international journal of neuropsychopharmacology · 2021Article
- Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.Pharmacological reviews · 2021Review
- Facilitation of GluN2C-containing NMDA receptors in the external globus pallidus increases firing of fast spiking neurons and improves motor function in a hemiparkinsonian mouse model.Neurobiology of disease · 2021Article
- GluN2D NMDA Receptors Gate Fear Extinction Learning and Interneuron Plasticity.Frontiers in synaptic neuroscience · 2021Article
- Modulation of burst firing of neurons in nucleus reticularis of the thalamus by GluN2C-containing NMDA receptors.Molecular pharmacology · 2019Article
- N-Methyl D-aspartate receptor subunit signaling in fear extinction.Psychopharmacology · 2019Review
- Structure, function, and allosteric modulation of NMDA receptors.The Journal of general physiology · 2018Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 2 countries.
Maja JessenDepartment of Molecular Screening, H. Lundbeck A/S, Valby, Denmark (M.J., K.F., A.D.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (M.J., R.P.C., H.B.-O.); Department of Medicinal Chemistry 1, H. Lundbeck A/S, Valby, Denmark (P.K.); Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (F.Y., K.B.H.).
Kristen FrederiksenDepartment of Molecular Screening, H. Lundbeck A/S, Valby, Denmark (M.J., K.F., A.D.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (M.J., R.P.C., H.B.-O.); Department of Medicinal Chemistry 1, H. Lundbeck A/S, Valby, Denmark (P.K.); Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (F.Y., K.B.H.) krf@lundbeck.com kasper.hansen@mso.umt.edu.
Feng YiDepartment of Molecular Screening, H. Lundbeck A/S, Valby, Denmark (M.J., K.F., A.D.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (M.J., R.P.C., H.B.-O.); Department of Medicinal Chemistry 1, H. Lundbeck A/S, Valby, Denmark (P.K.); Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (F.Y., K.B.H.).
Rasmus P ClausenDepartment of Molecular Screening, H. Lundbeck A/S, Valby, Denmark (M.J., K.F., A.D.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (M.J., R.P.C., H.B.-O.); Department of Medicinal Chemistry 1, H. Lundbeck A/S, Valby, Denmark (P.K.); Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (F.Y., K.B.H.).
Kasper B HansenDepartment of Molecular Screening, H. Lundbeck A/S, Valby, Denmark (M.J., K.F., A.D.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (M.J., R.P.C., H.B.-O.); Department of Medicinal Chemistry 1, H. Lundbeck A/S, Valby, Denmark (P.K.); Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (F.Y., K.B.H.) krf@lundbeck.com kasper.hansen@mso.umt.edu.
Hans Bräuner-OsborneDepartment of Molecular Screening, H. Lundbeck A/S, Valby, Denmark (M.J., K.F., A.D.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (M.J., R.P.C., H.B.-O.); Department of Medicinal Chemistry 1, H. Lundbeck A/S, Valby, Denmark (P.K.); Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (F.Y., K.B.H.).
Paul KilburnDepartment of Molecular Screening, H. Lundbeck A/S, Valby, Denmark (M.J., K.F., A.D.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (M.J., R.P.C., H.B.-O.); Department of Medicinal Chemistry 1, H. Lundbeck A/S, Valby, Denmark (P.K.); Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (F.Y., K.B.H.).
Anders DamholtDepartment of Molecular Screening, H. Lundbeck A/S, Valby, Denmark (M.J., K.F., A.D.); Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark (M.J., R.P.C., H.B.-O.); Department of Medicinal Chemistry 1, H. Lundbeck A/S, Valby, Denmark (P.K.); Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana (F.Y., K.B.H.).
University of Copenhagen · DKUniversity of Montana · USLundbeck (Denmark) · DK
Funding
Surveillance genome sequencing to detect SARS-CoV-2 virus variants in MontanaP20GM103546 · NIGMS · UNIVERSITY OF MONTANA · PI BOWLER, BRUCE E · 2012 to 2021
$19.2MStructural and functional investigation of negative allosteric NMDA receptor modulationR01NS097536 · NINDS · UNIVERSITY OF MONTANA · PI Kasper Boe Hansen · 2016 to 2026
$3.4MNIGMS NIH HHS P20 GM103546NINDS NIH HHS R01 NS097536
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsBinding SitesDose-Response Relationship, DrugExcitatory Amino Acid AgonistsGlycineHEK293 CellsHumansNerve Tissue ProteinsRatsReceptors, N-Methyl-D-AspartateXenopus laevisExcitatory Amino Acid AgonistsGlycineGprin1 protein, mouseNerve Tissue ProteinsNR2C NMDA receptorReceptors, N-Methyl-D-Aspartate
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.